{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:07:50Z","timestamp":1770070070004,"version":"3.49.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.esmoop.2023.101580","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T15:01:35Z","timestamp":1687964495000},"page":"101580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results"],"prefix":"10.1016","volume":"8","author":[{"given":"E.B.","family":"Garon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Novello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Ponce","family":"Aix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.D.","family":"Butts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Visseren-Grul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2023.101580_bib1","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101580_bib2","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdq189","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"D'addario","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mourino","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"48","key":"10.1016\/j.esmoop.2023.101580_bib4","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13000-019-0840-2","article-title":"The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies","volume":"14","author":"Ho","year":"2019","journal-title":"Diagn Pathol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2023.101580_bib6","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101580_bib7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101580_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101580_bib9","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00432-019-03001-2","article-title":"Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC","volume":"145","author":"Deng","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101580_bib10","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic value of TP53 concurrent mutations for EGFR\u2013 TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.esmoop.2023.101580_bib12","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101580_bib14","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.18632\/oncotarget.7189","article-title":"The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40487-018-0064-8","article-title":"Real-world EGFR T790M testing in advanced non-small-cell lung cancer: a prospective observational study in Japan","volume":"6","author":"Seto","year":"2018","journal-title":"Oncol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12885-018-4075-5","article-title":"Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101580_bib17","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/annonc\/mdx288","article-title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","volume":"28","author":"Mayo-de-Las-Casas","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101580_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.101580_bib20","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101580_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2019.12.016","article-title":"Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer","volume":"141","author":"Ebert","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101580_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1055-9965.EPI-14-0895","article-title":"Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis","volume":"24","author":"Qiu","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.esmoop.2023.101580_bib24","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/mdw531","article-title":"Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations","volume":"28","author":"Iwama","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2023.101580_bib26","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101580_bib27","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.18632\/oncotarget.6874","article-title":"Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2023.101580_bib28","article-title":"Dynamic cfDNA analysis by NGS in EGFR T790M-positive advanced NSCLC patients failed to the first-generation EGFR-TKIs","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101580_bib29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2023.101580_bib30","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.esmoop.2023.101580_bib31","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1158\/1078-0432.CCR-17-1745","article-title":"Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.esmoop.2023.101580_bib32","first-page":"JCO1800328","article-title":"Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing","volume":"36","author":"Slavin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101580_bib33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/gim.2017.196","article-title":"Somatic TP53 variants frequently confound germ-line testing results","volume":"20","author":"Weitzel","year":"2018","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101580_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41416-022-01777-8","article-title":"Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?","volume":"127","author":"Bonanno","year":"2022","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101580_bib35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101580_bib36","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.18632\/oncotarget.13915","article-title":"Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer","volume":"8","author":"Normanno","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2019.10.013","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I-IV non-small cell lung cancer","volume":"22","author":"Jiang","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"issue":"16","key":"10.1016\/j.esmoop.2023.101580_bib39","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/cncr.33571","article-title":"High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: the Korean Lung Liquid Versus Invasive Biopsy Program","volume":"127","author":"Park","year":"2021","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101580_bib40","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101580_bib41","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101580_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21037\/tlcr.2020.03.02","article-title":"EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib","volume":"9","author":"Buder","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"22","key":"10.1016\/j.esmoop.2023.101580_bib44","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","article-title":"Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.21037\/tlcr.2020.01.21","article-title":"Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling","volume":"9","author":"Shen","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.101580_bib48","article-title":"First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.101580_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.644472","article-title":"The impact of variant allele frequency in EGFR mutated NSCLC patients on targeted therapy","volume":"11","author":"Friedlaender","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib50","doi-asserted-by":"crossref","first-page":"662","DOI":"10.21037\/tlcr-20-814","article-title":"EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study","volume":"10","author":"Gieszer","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101580_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jtho.2020.11.022","article-title":"Altered regulation of HIF-1\u03b1 in naive- and drug-resistant EGFR-mutant NSCLC: implications for a vascular endothelial growth factor-dependent phenotype","volume":"16","author":"Nilsson","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101580_bib53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an\u00a0open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101580_bib56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CLC.2009.n.039","article-title":"Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway","volume":"10","author":"Nguyen","year":"2009","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib57","first-page":"7","article-title":"Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.esmoop.2023.101580_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ebiom.2019.03.023","article-title":"Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer","volume":"42","author":"Chen","year":"2019","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101580_bib59","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00109-007-0221-2","article-title":"Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome","volume":"85","author":"Teodoro","year":"2007","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101580_bib60","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","article-title":"VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy","volume":"75","author":"Schwaederle","year":"2015","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101580_bib61","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-11-2348","article-title":"p53 inhibits angiogenesis by inducing the production of Arresten","volume":"72","author":"Assadian","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101580_bib62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101580_bib63","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101580_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","article-title":"A\u00a0randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial","volume":"33","author":"Soo","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101580_bib65","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101580_bib66","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-20-1690","article-title":"Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer","volume":"27","author":"Yu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101580_bib67","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1\/2 single-group open-label trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101580_bib68","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"15_suppl","key":"10.1016\/j.esmoop.2023.101580_bib69","article-title":"A\u00a0multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833","volume":"37","author":"Nakahara","year":"2019","journal-title":"Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib70","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2023.101580_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2023.02.010","article-title":"RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome","author":"Nishio","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101580_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101580_bib73","doi-asserted-by":"crossref","first-page":"v149","DOI":"10.1093\/annonc\/mdz243.015","article-title":"405P - Association between TP53 mutations and efficacy of osimertinib for brain metastasis from EGFR-mutant lung cancer","volume":"30","author":"Chen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101580_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102861","article-title":"Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study","volume":"57","author":"Fukuhara","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101580_bib76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/gcc.22522","article-title":"Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer","volume":"57","author":"Liu","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41571-020-0423-x","article-title":"Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice","volume":"18","author":"Aggarwal","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101580_bib78","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101580_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101580_bib80","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/curroncol29030174","article-title":"Genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice","volume":"29","author":"Cho","year":"2022","journal-title":"Curr Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:56Z","timestamp":1761856196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2059702923008128"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101580","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101580"}}